References
- Goodrich G, Ardit A, Rubin G, Keeffe J, Legge G. The low vision timeline: An interactive history. Vis Impairment Res 2008; 10: 67–75.
- Australian Bureau of Statistics. Population Projections, Australia, 2006 to 2101 (cat. no. 3222.0). Canberra, Australia: Commonwealth of Australia, 2008.
- World Health Organization, US National Institute of Aging. Global Health and Aging. Bethesda, MD: National Institute of Aging, 2011.
- Taylor HR, Keeffe JE, Vu HT, Wang JJ, Rochtchina E, Pezzullo ML, Mitchell P. Vision loss in Australia. Med J Aust 2005; 182: 565–568.
- Binns AM, Bunce C, Dickinson C, Harper R, Tudor‐edwards R, Woodhouse M, Linck P et al. How effective is low vision service provision? A systematic review. Surv Ophthalmol 2012; 57: 34–65.
- Stelmack JA, Tand XC, Wei Y, Massof RW, the Low Vision Intervention Trial Study Group. The effectiveness of low vision rehabilitation in 2 cohorts dervied from the veteran affairs Low Vision Intervention Trial. Arch Ophthalmol 2012; 130: 1162–1168.
- Wang BZ, Pesudovs K, Keane MC, Daly A, Chen CS. Evaluating the effectiveness of multidisciplinary low vision rehabilitation. Optom Vis Sci 2012; 89: 1398–1408.
- Lamoureux EL, Pallant JF, Pesudovs K, Rees G, Hassell JB, Keeffe JE. The effectiveness of low vision rehabilitation on participation and quality of life. Invest Ophthalmol Vis Sci 2007; 48: 1476–1482.
- Lim HY, O'connor PM, Keeffe JE. Low vision services provided by optometrists in Victoria, Australia. Clin Exp Optom 2008; 91: 177–182.
- O'connor PE, Keeffe JE. Focus on Low vision. Melbourne, Australia: Centre for Eye Research Australia, 2007.
- Minassian DC, Reidy A, Lightstone A, Desai P. Modelling the prevalence of age‐related macular degeneration (2010–2020) in the UK: expected impact of anti‐vascular endothelial growth factor (VEGF) therapy. Br J Ophthalmol 2011; 95: 1433–1436.
- Sahel JA, Roska B. Gene therapy for blindness. Annu Rev Neurosci 2013; 36: 467–488.
- Colella P, Auricchio A. Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients. Hum Gene Ther 2012; 23: 796–807.
- Williams KA, Klebe S. Gene therapy for corneal dystrophies and disease, where are we? Curr Opin Ophthalmol 2012; 23: 276–279.
- Bharti K, Rao M, Hull SC, Stroncek D, Brooks BP, Feigal E, van Meurs JC et al. Developing cellular therapies for retinal degenerative diseases. Invest Ophthalmol Vis Sci 2014; 55: 1191–1202.
- Menzel‐severing J, Kruse FE, Schlötzer‐schrehardt U. Stem cell‐based therapy for corneal epithelial reconstruction: present and future. Can J Ophthalmol 2013; 48: 13–21.
- Weiland JD, Cho AK, Humayun MS. Retinal prostheses: current clinical results and future needs. Ophthalmology 2011; 118: 2227–2237.
- O'brien EE, Greferath U, Vessey KA, Jobling AI, Fletcher EL. Electronic restoration of vision in those with photoreceptor degenerations. Clin Exp Optom 2012; 95: 473–483.
- Keeffe J, Taylor HR, Fotis K, Pesudovs K, Flaxman SR, Jonas JB, Leasher J et al. Prevalence and causes of vision loss in Southeast Asia and Oceania: 1990–2010. Br J Ophthalmol 2014. Jan 9, [Epub ahead of print].
- Stevens GA, White RA, Flaxman SR, Price H, Jonas JB, Keeffe J, Leasher J et al. Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990–2010. Ophthalmology 2013; 120: 2377–2384.
- Bentley S, Jackson J, Johnson A, Napper G, Hodgson M, Soong G, Oberstein S et al. Advancing low vision services: A plan for Australian optometry. Clin Exp Optom 2014; 97: 214–220.
- Ryan B. Models of low vision care: Past, present and future. Clin Exp Optom 2014; 97: 209–213.
- Philip S, Dutton G. Identifying and characterising cerebral visual impairment in children: A review. Clin. Exp Optom 2014; 97: 196–208.